Overview
Portfolio
More
Sip Vc
Minato, Japan
Value-add investments in early and growth stage tech companies to enable market expansion into Japan, ASEAN and GCC regions.
Portfolio
13+
Employees
5+
Founded
N/A
AUM
≈ $150.0M
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
Gulf Cooperation CouncilJapanUnited States
Fund details
Funds
Fund I
Vintage 2021 • $150.0M
Sources
Sip Vc
Value-add investments in early and growth stage tech companies to enable market expansion into Japan, ASEAN and GCC regions.
Portfolio
13+
Employees
5+
Founded
N/A
AUM
≈ $150.0M
Funds
Fund I · Vintage 2021 • $150.0M
Stages
No stages listed
Industries
No industries listedGeographic scope
Gulf Cooperation CouncilJapanUnited States
Sources
Showing 8 of 8 matched portfolio companies
Ben is a unified platform that facilitates the learning, trading, and secure storage of cryptocurrency through a user-friendly interface. It addresses the challenges of fragmented access and security in the cryptocurrency market, enabling users to manage their digital assets efficiently.
DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.
Funding: $50.0K
Rough estimate of the amount of funding raised
Funding: $50.0K
Rough estimate of the amount of funding raised
IYO develops a screenless natural language computing platform that enables users to interact with audio applications through voice commands, facilitating tasks such as learning, shopping, and creating without visual distractions. This technology addresses the challenge of maintaining focus and presence in daily activities by providing a seamless audio-driven experience that enhances user engagement.
The startup operates a zero-knowledge oracle network for Ethereum, utilizing zero-knowledge proofs to facilitate secure off-chain computation for tasks such as automation and machine learning inference. This technology enhances the functionality and reliability of smart contracts, enabling developers to create more sophisticated decentralized applications without compromising on trust or security.
15+
500+Approximate amount of employees
Funding: $23.0M
Rough estimate of the amount of funding raised
Funding: $23.0M
Rough estimate of the amount of funding raised
Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.
Funding: $7.0M
Rough estimate of the amount of funding raised
Funding: $7.0M
Rough estimate of the amount of funding raised
RITS develops autonomous vehicle technologies, including customized 77GHz millimeter-wave radar and adaptive control algorithms for unstructured road conditions, to enhance the safety and efficiency of commercial vehicles. The company addresses the challenges of vehicle navigation and obstacle detection in adverse weather and complex environments, providing solutions such as automatic emergency braking and blind spot detection systems.
The startup utilizes computer vision and artificial intelligence to analyze and interpret visual content generated by brands in real time. This technology enables brands to gain actionable insights from their visual assets, enhancing their marketing strategies and engagement with audiences.
Physios Biotech develops microphysiological systems (MPS) that replicate human organ functions and rare disease environments, utilizing advanced nanotechnology for high human extrapolation. Their technology reduces reliance on animal testing and accelerates drug development timelines by providing accurate safety evaluations and therapeutic assessments for rare cancers.
Showing 5 of 5 unmatched portfolio companies